The primary role of this fixed-dose combination medication is to provide supportive symptomatic relief across core domains of obstructive lung disease, focusing primarily on easing symptom burden.

Bronchodilator combinations like this generally play a role in managing the symptoms of conditions where airway obstruction is a primary factor.

---

Management of Acute Asthma and Exacerbations

This solution is generally applied in clinical settings that involve acute or unstable symptom patterns associated with symptoms associated with acute or episodic changes. It is commonly used when symptoms such as severe shortness of breath and wheezing escalate rapidly, which is characteristic of acute asthma attacks or acute exacerbations of COPD. The main therapeutic benefit is providing short-term supportive relief that helps patients cope more steadily with difficult and potentially overwhelming episodes.

The combination is relevant for conditions characterized by periods of heightened symptoms, including Bronchial Asthma, Chronic Obstructive Pulmonary Disease (COPD), and chronic bronchitis where reversible airflow constriction is present.

---

Symptomatic Relief and Functional Support

“It helps address symptom clusters that may become intense or disruptive, assisting with maintaining functional stability.”

The medication is applied across domains where additional symptomatic support is needed, specifically targeting involuntary bronchial spasm. When experiencing symptoms that create noticeable physiological strain, the medication provides support that helps ease the overall symptom burden associated with heightened physiological activity. This action supports the patient during difficult episodes by easing distress, assisting with maintaining functional stability when symptoms interfere with routine activities.

---

Quick Fact: Relief for Acute Airflow Restriction The medication is commonly used when symptoms intensify and supportive relief is needed to address acute and pronounced bronchial spasm and the resulting difficulty breathing.

The official eligibility profile for Астмасол-СОЛОфарм is strictly defined by regulatory documents governing the Fenoterol and Ipratropium components.

---

Absolute Non-Eligibility

Use is contraindicated and the medicine must not be used in individuals with a known hypersensitivity to the active ingredients or to atropine-like substances. Absolute non-eligibility also applies to patients diagnosed with hypertrophic obstructive cardiomyopathy or tachyarrhythmia.

---

Age and Conditional Use Restrictions

Age: The medicine is established for adults and adolescents 12 years and older. Safety and efficacy are not established for children under 12.

Conditional Use: Use requires mandatory caution for populations with conditions such as narrow-angle glaucoma, prostatic hyperplasia (urinary outflow obstruction), severe cardiovascular disorders, uncontrolled diabetes mellitus, or hyperthyroidism. Caution is also advised during pregnancy and lactation, as well as in patients with renal or hepatic insufficiency where specific data has not been studied.

Астмасол-СОЛОфарм Interactions with other medicines and products

Official regulatory documentation details specific interaction patterns, primarily stemming from pharmacodynamic overlap. Co-administration with other β-mimetics or systemically available anticholinergics may increase the risk of adverse reactions. For instance, the concurrent use of this combination with Monoamine Oxidase Inhibitors (MAOIs) or Tricyclic Antidepressants (TCAs) may enhance the action of the Fenoterol component.

Conversely, co-administration with non-selective β-blockers may cause a potentially serious reduction in bronchodilatation, due to an antagonistic pharmacodynamic effect.

A central interaction is the increased risk of β2-agonist-induced hypokalaemia when the medication is combined with Xanthine derivatives, Corticosteroids, or Diuretics. This risk must be considered particularly in patients with severe airway obstruction, and hypokalaemia may lead to an increased susceptibility to arrhythmias in patients concurrently receiving Digoxin.

Administration Constraints

The regulatory label includes a procedural restriction: the inhalation solution must not be mixed with other drugs in the same nebulizer. Furthermore, the chronic co-administration with other anticholinergic drugs is not recommended.

How Астмасол-СОЛОфарм Works: A Dual Pathway Modulator

Астмасол-СОЛОфарм utilizes a dual mechanistic approach to influence the smooth muscle tone of the airways, with two agents acting on complementary branches of the autonomic nervous system. This complementary action results in a combined effect on airway diameter via dual mechanistic cascades.

Modulating the Parasympathetic Pathway (Anticholinergic Action)

This mechanism, mediated by Ipratropium bromide, involves the competitive inhibition of muscarinic receptors on bronchial smooth muscles. By binding to these receptors, it interrupts the action of acetylcholine released from the vagus nerve endings. This primarily results in the inhibition of vagally-mediated contraction of the bronchial smooth muscle.

Stimulating the Sympathetic Pathway (beta2-Agonism)

This mechanism, mediated by Fenoterol, involves the direct stimulation of beta2-adrenergic receptors. This interaction activates an intracellular sequence that increases cyclic AMP (cAMP), initiating cellular events that lead to the relaxation of bronchial smooth muscle fibers, influencing airway patency.

Cellular Cascade and Smooth Muscle Tension Control

The two distinct mechanistic pathways converge to influence the control of bronchial smooth muscle tension. By engaging both the cholinergic and beta2-adrenergic receptor systems, the drug alters the dynamic of smooth muscle contraction within the targeted pathways.

How to Use Астмасол-СОЛОфарм — Official Administration Guidelines

Астмасол-СОЛОфарм (Fenoterol and Ipratropium Bromide) is a solution strictly intended for administration via inhalation only using a nebulizer device. The product must not be swallowed or administered by any other route.

---

Dosing and Preparation

Usage involves two distinct dosing regimens: one for acute episodes and one for maintenance. For all administrations, the concentrated dose must be diluted with sterile physiological saline (0.9% NaCl) to achieve a final inhalation volume of 3 ml to 4 ml. The diluted solution must be freshly prepared before each use, and any leftover solution must be discarded.

Usage Context	Standard Labeled Dosing (Concentrate Volume)	Frequency Pattern
Acute Bronchospasm (Adults)	Typically 1.0 ml to 2.5 ml (Max single dose: 4.0 ml)	As-needed (repeated until relief, under supervision)
Maintenance/Intermittent Use	1.0 ml to 2.0 ml	Generally 3 to 4 times daily

---

Procedural and Population Rules

Administration should be performed using a mouthpiece or a properly fitting mask. A key procedural condition is that administration must be stopped immediately once adequate symptomatic relief is achieved, regardless of the volume remaining in the nebulizer.

Age-Group Rules: Specific pediatric dose ranges exist. For children aged 6–12 years, the dose ranges from 0.5 ml to 2.0 ml. For children under 6 years, dosing is weight-based (max 0.5 ml) and requires strict medical supervision.

These instructions establish the standardized, non-oral, and dilution-dependent protocol for using the medication, outlining precise volumes and frequencies for both acute and long-term use scenarios.

Астмасол-СОЛОфарм: Recent Clinical Evidence

The active ingredient in Астмасол-СОЛОфарм is Ipratropium Bromide, a short-acting anticholinergic bronchodilator. Research primarily focuses on its role in treating reversible bronchospasm associated with obstructive airway diseases, including asthma.

Efficacy and Outcome Measures

Clinical trials involving ipratropium have examined its effects on lung function, often measured by forced expiratory volume in one second (FEV1).

• Lung Function: Studies evaluate whether the administration of ipratropium is associated with increased FEV1 levels and other spirometry readings, indicating a widening of the airways. The onset of action, or time to a measurable improvement in pulmonary function, is typically reported to occur within 15 minutes of inhalation.
• Combination Therapy: Research frequently assesses ipratropium's use as an add-on treatment, particularly in combination with short-acting beta-agonists (SABAs), to investigate potential cumulative effects on improving airflow.

Safety and Tolerability Profile

Safety data is typically collected through clinical trials and post-marketing surveillance to assess adverse events and tolerability.

• Reported Adverse Events: Common adverse events reported in clinical studies include dry mouth, coughing, and irritation of the throat. Systemic absorption of the drug via inhalation is generally poor, which may contribute to a reduced incidence of systemic side effects compared to other routes of administration.
• Long-Term Research: Extended-duration studies have been conducted to evaluate the safety profile of the compound over time, especially in populations with chronic obstructive respiratory conditions, tracking the incidence of both common and rare adverse events.

Key Studies & References

1. Ipratropium - StatPearls (Source for Pharmacokinetics and Onset of Action)
2. Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease

Common questions about Астмасол-СОЛОфарм (FAQ)

---

Q: How fast does Астмасол-СОЛОфарм start working after inhalation?

Studies and official product information indicate that the anticholinergic component (Ipratropium) typically shows an onset of effect within approximately 15 minutes following inhalation. The Fenoterol component, a beta2-agonist, is intended to contribute to the onset of effect.

---

Q: How should I dispose of the leftover or expired medication?

Regulatory guidance states that all unused or expired medicine must be safely discarded. General instructions, such as those from the FDA, often suggest mixing unused medicine with an undesirable substance (like coffee grounds or kitty litter) and placing it in a sealed container before disposal in household trash. Drug take-back programs are also an option where available.

---

Q: What are the consequences of mixing this inhalation solution with other drugs in the nebulizer?

Official information strictly states that the solution must not be mixed with other drugs in the same nebulizer. This restriction is based on the potential for incompatibilities and the documented risk of adverse reactions, such as acute closed-angle glaucoma, particularly if the nebulized solution accidentally contacts the eyes.

---

Q: How does this drug interact with Digoxin?

Regulatory documents describe a potential drug interaction related to the Fenoterol component, which can lower blood potassium levels (hypokalemia). This reduction in potassium has been associated with an increased susceptibility to heart rhythm disorders (arrhythmias) in individuals also receiving Digoxin.

---

Q: What should I do if I miss a scheduled dose?

According to the official patient information, if a dose is forgotten, the general guidance is to take a forgotten dose as soon as it is remembered. The next dose can then be taken at its usual scheduled time. The guidance is to avoid taking two doses at once to compensate for the missed dose.

---

Q: Is it safe to use this medication while breastfeeding (lactation)?

Official information indicates that it is not fully known if this drug is passed into human milk. Due to this uncertainty, caution is advised when the medicine is administered to a nursing mother. The decision to use this medicine during lactation involves balancing the potential benefit to the mother against the potential risk to the infant.

---

Q: Can I use an ultrasonic nebulizer, or must I use a jet nebulizer?

Regulatory information specifies that the medicine must be administered using a power-operated nebulizer that has an adequate flow rate and is equipped with a mouthpiece or mask. For specific device types, it is recommended to refer to the instructions provided by a healthcare professional or the nebulizer device manufacturer.

---

Q: Does the packaging contain a patient information leaflet (PIL)?

Yes, regulatory requirements mandate that all prescription medicine packaging include a Patient Information Leaflet (PIL), also known as a Package Leaflet. This leaflet provides essential instructions for use, warnings, and detailed safety information.

---

Q: What if I accidentally swallow the solution instead of inhaling it?

The product is strictly intended for inhalation. Official data suggests that only a small amount of the Ipratropium component is absorbed systemically after swallowing, meaning severe systemic effects are not expected at typical therapeutic doses. However, any accidental ingestion should be reported to a healthcare professional for guidance.

---

Official Storage and Disposal Requirements

Астмасол-СОЛОфарм (Fenoterol and Ipratropium Bromide inhalation solution) must be stored and disposed of according to explicit regulatory conditions to maintain stability and effectiveness.

Storage Requirement	Official Condition
Temperature Range	Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F) [Source 1.7].
Prohibited Conditions	Do not freeze and keep the medicine away from excessive heat [Source 3.1].
Protection	Vials must be stored in the original foil pouch or carton to protect the solution from light [Source 1.7].
Stability Check	The solution should be clear and colorless; if it is discolored, the product must be discarded [Source 2.3].
Child Safety	The medicine must be kept out of the reach of children [Source 1.7].
Disposal	All unused or expired medicine must be safely discarded [Source 1.7]. Consult a healthcare professional or pharmacist for instructions on local disposal procedures [Source 3.1].